- Published on
These Patients Couldn't Beat Lyme Disease, So Scientists Tried Giving Them Psilocybin
- Authors
- Name
- DeepHorus
A groundbreaking pilot study from Johns Hopkins University suggests psilocybin may offer significant relief for patients suffering from persistent symptoms after Lyme disease treatment. The research, led by Albert Garcia-Romeu at the Johns Hopkins Center for Psychedelic and Consciousness Research and published in Scientific Reports, provides a new potential avenue for a condition with limited treatment options.
Lyme disease is the most common vector-borne illness in the United States, affecting nearly 500,000 people annually. While antibiotics are effective for many, a substantial subset develops post-treatment Lyme disease, or PTLD. These patients endure debilitating symptoms like fatigue, brain fog, and chronic pain for months or years after the initial infection has cleared.
The small pilot study involved 20 participants with PTLD who received two clinically supervised doses of psilocybin. The results were striking. Two weeks after the second dose, participants reported a 52% reduction in their overall symptom burden compared to baseline measurements.
Positive effects were sustained over time. Six months later, symptoms remained roughly 40-50% below initial levels. Specific metrics showed depressive symptoms were 50-60% lower, sleep disturbance improved by 40-50%, and total pain scores dropped approximately 40-50% throughout the trial.
The authors describe these findings as "sufficiently positive" but caution that the study is preliminary. It lacks a control group, randomization, or blinding, meaning scientists cannot yet definitively establish a causal link between psilocybin and symptom improvement. Rigorous, larger-scale trials are now needed.
PTLD shares symptoms with other post-viral illnesses like long COVID and ME/CFS, where effective treatments are also lacking. This gap in care is driving researchers and patients to explore psychedelic-assisted therapy, as seen in recent pilot trials for fibromyalgia and anecdotal cases for long COVID.
The research team concludes that further investigation of psychedelics is warranted for PTLD and similar chronic conditions. This emerging field hopes to validate a treatment for the hundreds of thousands who continue to suffer long after a tick bite.
